New combo therapy shows promise for uterine condition in obese women
NCT ID NCT05172999
First seen Mar 17, 2026 · Last updated Jun 18, 2026 · Updated 8 times
Summary
This study tested whether adding a diabetes drug (polyethylene glycol loxenatide) to a hormone-releasing IUD (LNG-IUS) helps women with a precancerous uterine condition called endometrial atypical hyperplasia. The 30 participants were all obese and wanted to preserve their fertility or keep their uterus. The goal was to see if the combination led to a complete disappearance of abnormal cells within 32 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, 200090, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.